Skip to main content

Pioneering a new generation

of gut-targeted

polymer therapies

Corporate Overview

Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity.

The company evolved from the founding team’s research on how certain types of bariatric surgeries lead to significant improvements in glucose and metabolic regulation as well as sustained weight loss.

Using our Mucus Complexing Polymer (MCP) platform invented through research originating at Johns Hopkins University, Glyscend is targeting mechanisms inside the GI tract to treat a variety of metabolic and chronic conditions. In addition, the company is exploring program opportunities that address topical GI as well as GI-mediated systemic metabolic, inflammatory, and autoimmune conditions.

Decades of experience in gastroenterology, metabolism, polymer chemistry, and drug development

Our executive team

The team’s combined experience in gastroenterology, metabolism, polymer chemistry, and drug development is key to advancing a new generation of polymer therapies for treating T2D and obesity with the goal of improving patient outcomes and reducing costs across the healthcare system.

Sapan Shah, PhD

Chief Executive Officer

Ashish Nimgaonkar, PhD

Ashish Nimgaonkar, MD

Chief Medical Officer & Head of R&D

Mark Fineman, PhD

Chief Development Officer

Thomas Josefiak, PhD

Thomas Jozefiak, PhD

Chief Scientific Officer

Kevin Colbert

Sr. Director Operations & Strategy

Christine Bryant, PhD

Sr. Director Clinical & Translational Science

Boards

Alain Baron, MD | Endocrinologist, Past CEO, Elcelyx
John Buse, MD, PhD | Endocrinologist, UNC Chapel Hill
Ralph Defronzo, MD | Endocrinologist, Nephrologist, U of Texas Health
Michael Horowitz, MD, PhD | Endocrinologist, U of Adelaide
Lee Kaplan, MD, PhD | Director, Obesity, Metabolism & Nutrition Institute, Mass General
Jay Pasricha, MD | Chair, Dept of Medicine, Mayo Clinic Arizona
Chris Rayner, MD, PhD | Gastroenterologist, U of Adelaide
Randy Seeley, PhD | Director, Michigan Nutrition Obesity Research Center
Jiten Vora, MD | Endocrinologist, U of Liverpool
Andrew Young, MD, PhD | CSO, Intarcia Therapeutics
Louis Bock | Partner, Santé Ventures
Dennis McWilliams | Partner, Santé Ventures
Leighton Read, MD | Partner, Brandon Capital Partners
Sapan Shah, PhD | CEO, Glyscend
Bob Soh, MD | Partner, Brandon Capital Partners
Karen Talmadge, PhD | Former Chair of ADA
Michael Wyzga, MBA | Former CFO Genzyme
Close Menu

About Glyscend, Inc.

1812 Ashland Avenue, Suite 110
Baltimore, MD 21205, USA

600 Suffolk Street, Suite 250
Lowell, MA 01854-3643, USA